gastroenterology-2017-scientifictrack-abstracts

10 / 12

Page 37
Notes:
conferenceseries .com
Volume 7, Issue 5 (Suppl) J Gastrointest Dig Syst, an open access journal
ISSN:2161-069X Gastroenterology 2017
November 13-14, 2017
November 13-14, 2017 | Las Vegas, USA
13th International Conference on
Clinical Gastroenterology, Hepatology and Endoscopy
Probiotics and chronic liver diseases
Leopoldo R Arosemena
University of Miami, USA
It has been proposed that alterations in the highly complex gut microbiome leads to intestinal barrier damage and the release of
pro-inflammatory endotoxins to the portal circulation, which trigger variable injuries in the liver and subsequently in the rest
of the body. In return, the liver influences intestinal function by producing bile (including bile acids), which are then modified
by intestinal bacteria (gut-liver axis). We are improving our understanding of those interactions at the molecular level, but we
are still far from mastering this knowledge. Multiple studies show that beneficial bacteria (probiotics) introduced in an abnormal
environment (dysbiosis) can induce improvements in different clinical outcomes. Many hepatopathies have been associated with
a decrease in the diversity of species living in the intestine and predominance of species considered pro-inflammatory. Research
groups around the world are closer to elucidate which combination of microorganisms can be used to affect positively certain
diseases in individuals. A review of the pathophysiology of diseases like alcoholic liver disease, NASH, viral hepatitis, inflammatory
hepatopathies, hepatocellular carcinoma, hepatic fibrogenesis indicate a close relationship among dietary factors, microbiome
and genetic predisposition. Modification of the intestinal milieu by antibiotics, probiotics, prebiotics (probiotic food), symbiotic
(prebiotics and probiotics) and surgical procedures, can lead to regression of multiple manifestations of chronic liver and systemic
inflammation. When we consider the heterogeneity of the studies and individual variations on gut microbiome, it is remarkable
how fast we have developed the technology to obtain more consistent results in research and clinical practice. Different species of
Lactobacillus, Bifidobacterium and Saccharomyces independently or in combinations have the most published data indicating decrease
on multiple inflammatory markers. Most of the data available is done in pre-clinical settings, but human studies are confirming many
of those concepts, including data on safety and effectiveness.
Biography
Leopoldo R Arosemena is a Transplant Hepatologist at the Miami Transplant Institute of the University of Miami. He has obtained his Medical degree at Universidad Autono-
ma de Nuevo Leon, in Monterrey, Mexico. Subsequently, he was accepted by the University of Internal Medicine program, where he achieved “Excellence in Achievement
and The Outstanding Presentation Award” as part of the Resident Scholarly Activity in 2003. Later, he has completed subspecialty fellowships in Hepatology, Transplant
Hepatology, earning a “Certificate of Excellence in the Young Investigator’s Forum” in Breckenridge, Colorado in 2004. He has also completed his training in Gastroenterolo-
gy at the University of Miami. He was the Medical Director of the Broward General Medical Center Liver transplant program from 2010 to 2012. He has multiple publications,
including a poster that received the “Presidential Award of the AASLD” at the 2009 in Liver Meeting. His main interest is in transplant hepatology and nutrition.
Leopoldo R Arosemena, J Gastrointest Dig Syst 2017, 7:5 (Suppl)
DOI: 10.4172/2161-069X-C1-055